UA129403C2 - Елацестрант в комбінації з абемациклібом у жінок з раком молочної залози - Google Patents
Елацестрант в комбінації з абемациклібом у жінок з раком молочної залози Download PDFInfo
- Publication number
- UA129403C2 UA129403C2 UAA202102817A UAA202102817A UA129403C2 UA 129403 C2 UA129403 C2 UA 129403C2 UA A202102817 A UAA202102817 A UA A202102817A UA A202102817 A UAA202102817 A UA A202102817A UA 129403 C2 UA129403 C2 UA 129403C2
- Authority
- UA
- Ukraine
- Prior art keywords
- patient
- abemaciclib
- dose
- administered
- day
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862773960P | 2018-11-30 | 2018-11-30 | |
| PCT/US2019/063239 WO2020112765A1 (en) | 2018-11-30 | 2019-11-26 | Elacestrant in combination with abemaciclib in women with breast cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA129403C2 true UA129403C2 (uk) | 2025-04-16 |
Family
ID=68966023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA202102817A UA129403C2 (uk) | 2018-11-30 | 2019-11-26 | Елацестрант в комбінації з абемациклібом у жінок з раком молочної залози |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US20220117963A1 (https=) |
| EP (1) | EP3886826A1 (https=) |
| JP (2) | JP2022509262A (https=) |
| KR (1) | KR20210097170A (https=) |
| CN (1) | CN113164415A (https=) |
| AU (1) | AU2019388900B2 (https=) |
| BR (1) | BR112021010169A2 (https=) |
| CA (1) | CA3120368A1 (https=) |
| EA (1) | EA202191165A1 (https=) |
| IL (1) | IL283502A (https=) |
| JO (1) | JOP20210125A1 (https=) |
| MA (1) | MA54293A (https=) |
| MX (1) | MX2021005876A (https=) |
| MY (1) | MY209833A (https=) |
| PH (1) | PH12021551235A1 (https=) |
| SG (1) | SG11202105455RA (https=) |
| UA (1) | UA129403C2 (https=) |
| WO (1) | WO2020112765A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021003440A2 (pt) | 2018-09-07 | 2021-05-18 | Sanofi | sais de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil) pirrolidin-3-il]oxifenil]-8,9-di-hidro-7h-benzo[7]anuleno-2-carboxilato de metila e seu processo de preparação |
| EP4037768B1 (en) | 2019-10-01 | 2023-10-11 | Sanofi | Novel substituted 6,7-dihydro-5h-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof |
| AU2020399168A1 (en) | 2019-12-09 | 2022-07-28 | Sanofi | Crystalline form of a 7H-benzo[7]annulene-2-carboxylic acid derivative |
| TW202146007A (zh) | 2020-02-27 | 2021-12-16 | 法商賽諾菲公司 | 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合 |
| TW202233572A (zh) | 2020-10-19 | 2022-09-01 | 法商賽諾菲公司 | 新穎之經取代的6,7-二氫-5h-苯並[7]輪烯衍生物，其製備方法及其治療用途 |
| WO2022084280A1 (en) | 2020-10-19 | 2022-04-28 | Sanofi | Substituted 6,7-dihydro-5h-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof |
| WO2022106711A1 (en) * | 2020-11-23 | 2022-05-27 | Sanofi | Combination comprising abemaciclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid |
| CN114146182A (zh) * | 2021-11-12 | 2022-03-08 | 深圳大学 | Cdk4/6抑制剂与铂类化疗药物在制备治疗肿瘤的药物中的用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250152679A (ko) * | 2015-04-29 | 2025-10-23 | 래디어스 파마슈티컬스, 인코포레이티드 | 암을 치료하는 방법 |
| AU2017235450A1 (en) * | 2016-03-15 | 2018-08-16 | Merrimack Pharmaceuticals, Inc. | Methods for treating ER+, HER2-, HRG+ breast cancer using combination therapies comprising an anti-ErbB3 antibody |
| WO2018017410A1 (en) * | 2016-07-22 | 2018-01-25 | Eli Lilly And Company | Combination therapy of abemaciclib and a pi3 kinase/mtor dual inhibitor for use in the treatment of breast cancer |
-
2019
- 2019-11-26 MX MX2021005876A patent/MX2021005876A/es unknown
- 2019-11-26 KR KR1020217020321A patent/KR20210097170A/ko not_active Ceased
- 2019-11-26 EP EP19824087.1A patent/EP3886826A1/en active Pending
- 2019-11-26 MY MYPI2021002887A patent/MY209833A/en unknown
- 2019-11-26 MA MA054293A patent/MA54293A/fr unknown
- 2019-11-26 UA UAA202102817A patent/UA129403C2/uk unknown
- 2019-11-26 AU AU2019388900A patent/AU2019388900B2/en active Active
- 2019-11-26 EA EA202191165A patent/EA202191165A1/ru unknown
- 2019-11-26 US US17/298,198 patent/US20220117963A1/en not_active Abandoned
- 2019-11-26 WO PCT/US2019/063239 patent/WO2020112765A1/en not_active Ceased
- 2019-11-26 JO JOP/2021/0125A patent/JOP20210125A1/ar unknown
- 2019-11-26 SG SG11202105455RA patent/SG11202105455RA/en unknown
- 2019-11-26 CA CA3120368A patent/CA3120368A1/en active Pending
- 2019-11-26 BR BR112021010169-1A patent/BR112021010169A2/pt unknown
- 2019-11-26 JP JP2021530913A patent/JP2022509262A/ja active Pending
- 2019-11-26 CN CN201980079089.6A patent/CN113164415A/zh active Pending
-
2021
- 2021-05-27 IL IL283502A patent/IL283502A/en unknown
- 2021-05-28 PH PH12021551235A patent/PH12021551235A1/en unknown
-
2025
- 2025-03-25 JP JP2025050208A patent/JP2025094216A/ja active Pending
- 2025-05-02 US US19/197,091 patent/US20250268899A1/en active Pending
- 2025-09-24 US US19/338,117 patent/US20260014153A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JOP20210125A1 (ar) | 2019-11-26 |
| EP3886826A1 (en) | 2021-10-06 |
| WO2020112765A1 (en) | 2020-06-04 |
| MA54293A (fr) | 2021-10-06 |
| BR112021010169A2 (pt) | 2021-08-17 |
| MY209833A (en) | 2025-08-07 |
| JP2025094216A (ja) | 2025-06-24 |
| CN113164415A (zh) | 2021-07-23 |
| SG11202105455RA (en) | 2021-06-29 |
| KR20210097170A (ko) | 2021-08-06 |
| PH12021551235A1 (en) | 2021-12-13 |
| US20260014153A1 (en) | 2026-01-15 |
| EA202191165A1 (ru) | 2021-09-21 |
| AU2019388900B2 (en) | 2025-09-04 |
| CA3120368A1 (en) | 2020-06-04 |
| US20250268899A1 (en) | 2025-08-28 |
| AU2019388900A1 (en) | 2021-06-10 |
| JP2022509262A (ja) | 2022-01-20 |
| IL283502A (en) | 2021-07-29 |
| US20220117963A1 (en) | 2022-04-21 |
| MX2021005876A (es) | 2021-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA129403C2 (uk) | Елацестрант в комбінації з абемациклібом у жінок з раком молочної залози | |
| US11413258B2 (en) | Methods for treating cancer | |
| Fishman et al. | Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma | |
| US20230172928A1 (en) | Pharmaceutical combination comprising tno155 and nazartinib | |
| Lewin et al. | A phase 1b trial of selinexor, a first-in-class selective inhibitor of nuclear export (SINE), in combination with doxorubicin in patients with advanced soft tissue sarcomas (STS) | |
| RU2841076C2 (ru) | Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы | |
| KR20230165795A (ko) | 벨바라페닙 및 코비메티닙 또는 벨바라페닙, 코비메티닙 및 아테졸리주맙을 이용한 병용 요법 | |
| KR20250019775A (ko) | 암 치료를 위한 조성물 및 방법 | |
| DK2994126T3 (en) | Combination of a PI3 kinase inhibitor with paclitaxel for use in the treatment or prevention of head and neck cancer | |
| AU2012271041A1 (en) | Dosage and administration of anti-ErbB3 antibodies in combination with tyrosine kinase inhibitors |